Pre-Open Stock Movers 07/13: (DPW) (PLXP) (MSEX) Higher; (SLP) (TWO) (AFIB) Lower (more...)
Pre-Open Stock Movers:
Ault Global Holdings, Inc. (NYSE: DPW) 23% HIGHER; Q2 2021 Revenue of Approximately $62 million, up 1048% From the Prior Years Quarter
PLx Pharma Inc. (NASDAQ: PLXP) 16.8% HIGHER; announced that three stock-keeping units (SKUs) of VAZALORE, the first and only U.S. Food and Drug Administration (FDA) approved liquid-filled aspirin capsules, will be available in over 4,500 Walmart stores across the United States in mid-August.
Simulations Plus (NASDAQ: SLP) 14.8% LOWER; reported Q3 EPS of $0.18, in-line with the analyst estimate of $0.18. Revenue for the quarter came in at $12.8 million versus the consensus estimate of $14.74 million.
Middlesex Water Co. (NASD: MSEX) 11% HIGHER; will replace Luminex Corp. (NASD: LMNX) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, July 15
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) 9.6% HIGHER; announced today that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant virus SARS-CoV-2 at a highly effective level (~20ng/mL). Binding analyses project that AR-712 will be effective against all variants on the U.S. Centers for Disease Control's Variants of Interest and Variants of Concern lists.
Two Harbors Investment Corp. (NYSE: TWO) 8.2% LOWER; announced that it has commenced an underwritten public offering of 40,000,000 shares of its common stock.
Acutus Medical (NASDAQ: AFIB) 7.5% LOWER; announces 5,500,000 share offering
Nokia (NYSE: NOK) 7.5% HIGHER; expects to revise upwards its 2021 financial guidance
Equillium, Inc. (Nasdaq: EQ) 6.2% HIGHER; announced the completion of an End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) for itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD). The meeting confirmed a path to advance itolizumab into a single Phase 3 pivotal study to support the Biologics License Application (BLA) filing for itolizumab in first-line treatment of aGVHD patients. The company plans to initiate the Phase 3 study in Q4 2021.
VOXX Int'l (NASDAQ: VOXX) 6.1% LOWER; reported Q1 EPS of $0.11, versus ($0.34) reported last year. Revenue for the quarter came in at $137.1 million, versus $72 million reported last year.
Olink Holding AB (publ) (Nasdaq: OLK) 6.1% LOWER; announced the launch of a public offering of 7,000,000 American Depositary Shares, each representing one common share of the Company (the “ADSs”), to be sold by certain selling shareholders of the Company.
Hanesbrands (NYSE: HBI) 3.4% HIGHER; Wells Fargo upgraded from Equal Weight to Overweight with a price target of $23.00 (from $20.00).
IVERIC bio, Inc. (Nasdaq: ISEE) 3.4% LOWER; announced that it is commencing an underwritten public offering of shares of its common stock. In addition, the Company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares of its common stock.
ConAgra Brands (NYSE: CAG) 3.3% LOWER; reported Q4 EPS of $0.54, $0.02 better than the analyst estimate of $0.52. Revenue for the quarter came in at $2.74 billion versus the consensus estimate of $2.71 billion. ConAgra Brands sees FY2022 EPS of $2.50, versus the consensus of $2.63.
Tempest Therapeutics (NASDAQ: TPST) 3.3% HIGHER; H.C. Wainwright initiates coverage with a Buy rating and a price target of $51.00.
ChargePoint Holdings, Inc. (NYSE: CHPT) 3.3% LOWER; announced today that certain selling stockholders intend to offer 12,000,000 shares of the Company’s common stock.
Shoals Technologies Group, Inc. (Nasdaq: SHLS) 2.5% LOWER; announced the launch of an underwritten public offering of an aggregate of 13,384,155 shares of the Companys Class A common stock.
Byrna Technologies Inc. (NASDAQ: BYRN) 2.1% LOWER; announced that it has launched an underwritten public offering of 2,250,000 common shares.
Goldman Sachs (NYSE: GS) 1.5% HIGHER; reported Q2 EPS of $15.02, $4.79 better than the analyst estimate of $10.23. Revenue for the quarter came in at $15.39 billion versus the consensus estimate of $12.17 billion.
PepsiCo (NASDAQ: PEP) 1.2% HIGHER; reported Q2 EPS of $1.72, $0.19 better than the analyst estimate of $1.53. Revenue for the quarter came in at $19.22 billion versus the consensus estimate of $17.97 billion. PepsiCo sees FY2021 EPS of $6.20, versus the consensus of $6.09.
Celldex Therapeutics, Inc. (Nasdaq: CLDX) 0.8% LOWER; announced that it is proposing to offer and sell, subject to market conditions, $175 million of shares of its common stock in an underwritten public offering